{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:49:58Z","timestamp":1791614998451,"version":"4.3.4"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":43,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sodium\u2013glucose cotransporter-2 inhibitors (SGLT2i) have become the standard of care in managing chronic kidney disease (CKD) and heart failure (HF), both in patients with and without type 2 diabetes mellitus (T2DM). Nonetheless, identifying those at persistent high cardiovascular (CV) and renal risk remains critical.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective, 1:1 propensity-matched cohort study involving 132 CKD patients (66 with T2D and 66 without). Participants were followed for 12 months after SGLT2i initiation. Cardiovascular and renal risk were assessed using three validated tools\u2014PREVENT, SCORE2 with CKD Add-on (SCORE2-CKD), and Kidney Failure Risk Equation (KFRE)\u2014calculated at baseline and at 12-month follow-up. Changes in risk\u00a0scores were analyzed, and logistic regression was used to identify predictors of improvement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After 12 months, PREVENT scores declined significantly in the diabetic subgroup (\u0394 \u22122.95, P = .001), whereas non-diabetic patients showed no significant change (\u0394 \u22120.80, P = .396). SCORE2-CKD also decreased in diabetics (\u0394 \u22123.85, 95% CI \u22124.35 to \u22123.35, P = .023) but unexpectedly increased in non-diabetic patients (\u0394 + 3.25, P = .044). Importantly, individuals at higher baseline risk exhibited the most pronounced declines in both PREVENT and SCORE2-CKD. KFRE-derived renal risk decreased significantly in both groups. Across the entire cohort, variation in estimated glomerular filtration rate (eGFR) and proteinuria were independent predictors of CV risk-score improvement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this real-world CKD cohort, SGLT2 inhibitor initiation was associated with favorable changes in renal risk scores and with changes in cardiovascular risk estimates, particularly among patients with diabetes and at\u00a0higher baseline risk. These findings should be interpreted as exploratory changes in predicted risk rather than as evidence of reduction in observed cardiovascular events.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/joneph\/aajag105","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T11:44:41Z","timestamp":1779363881000},"page":"1246-1256","source":"Crossref","is-referenced-by-count":0,"title":["Longitudinal changes in cardiorenal risk scores after SGLT2 inhibitor initiation in patients with CKD with and\u00a0without type 2 diabetes"],"prefix":"10.1093","volume":"39","author":[{"given":"Irene","family":"Capelli","sequence":"first","affiliation":[{"name":"Nephrology, Dialysis and Kidney Transplant Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna , Bologna ,","place":["Italy"]},{"name":"Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum University of Bologna , Bologna ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6263-6202","authenticated-orcid":false,"given":"Daniele","family":"Vetrano","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum University of Bologna , Bologna ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danilo","family":"Ribichini","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Diabetes Prevention and Care, IRCCS Azienda Ospedaliero-Universitaria di Bologna , Bologna ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2168-702X","authenticated-orcid":false,"given":"Michele","family":"Provenzano","sequence":"additional","affiliation":[{"name":"Nephrology, Dialysis and Renal Transplant Unit, Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Rende - Hospital \u2018SS. Annunziata\u2019 , Cosenza ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasha","family":"Albertini","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum University of Bologna , Bologna ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7843-3716","authenticated-orcid":false,"given":"Sabrina","family":"Berti","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum University of Bologna , Bologna ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilirjana","family":"Sanfilippo","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum University of Bologna , Bologna ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Vicennati","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum University of Bologna , Bologna ,","place":["Italy"]},{"name":"Division of Endocrinology and Diabetes Prevention and Care, IRCCS Azienda Ospedaliero-Universitaria di Bologna , Bologna ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4182-3110","authenticated-orcid":false,"given":"Uberto","family":"Pagotto","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum University of Bologna , Bologna ,","place":["Italy"]},{"name":"Division of Endocrinology and Diabetes Prevention and Care, IRCCS Azienda Ospedaliero-Universitaria di Bologna , Bologna ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5473-8551","authenticated-orcid":false,"given":"Gaetano","family":"La Manna","sequence":"additional","affiliation":[{"name":"Nephrology, Dialysis and Kidney Transplant Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna , Bologna ,","place":["Italy"]},{"name":"Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum University of Bologna , Bologna ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Cianciolo","sequence":"additional","affiliation":[{"name":"Nephrology, Dialysis and Kidney Transplant Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna , Bologna ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"2026101002222617200_aajag105-B1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.kisu.2021.11.003","article-title":"Epidemiology of chronic kidney disease: an update 2022","volume":"12","author":"Kovesdy","year":"2022","journal-title":"Kidney Int Suppl"},{"key":"2026101002222617200_aajag105-B2","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0140\u20136736(21)01330\u20131","article-title":"Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants","volume":"398","author":"NCD Risk Factor Collaboration (NCD-RisC)","year":"2021","journal-title":"Lancet"},{"key":"2026101002222617200_aajag105-B3","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/S0140\u20136736(23)02750\u20132","article-title":"Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults","volume":"403","author":"NCD Risk Factor Collaboration (NCD-RisC)","year":"2024","journal-title":"Lancet"},{"key":"2026101002222617200_aajag105-B4","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1016\/S0140\u20136736(24)02317\u20131","article-title":"Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants [published correction appears in Lancet. 2025 Apr 5;405(10485):1146. doi:10.1016\/S0140\u20136736(25)00620\u20138.]","volume":"404","author":"NCD Risk Factor Collaboration (NCD-RisC)","year":"2024","journal-title":"Lancet"},{"key":"2026101002222617200_aajag105-B5","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s12933\u2013023\u201301937-x","article-title":"The cardio-renal-metabolic connection: a review of the evidence","volume":"22","author":"Marassi","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"2026101002222617200_aajag105-B6","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1111\/dom.14074","article-title":"Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: a large multinational cohort study","volume":"22","author":"Birkeland","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"2026101002222617200_aajag105-B7","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1001\/jama.2023.17002","article-title":"Estimated glomerular filtration rate, albuminuria, and adverse outcomes: an individual-participant data meta-analysis","volume":"330","author":"Writing Group for the CKD Prognosis Consortium","year":"2023","journal-title":"JAMA"},{"key":"2026101002222617200_aajag105-B8","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/S2213\u20138587(15)00040\u20136","article-title":"Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data","volume":"3","author":"Matsushita","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026101002222617200_aajag105-B9","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1093\/eurheartj\/ehab309","article-title":"SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe","volume":"42","author":"SCORE2 working group and ESC Cardiovascular risk collaboration","year":"2021","journal-title":"Eur Heart J."},{"key":"2026101002222617200_aajag105-B10","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1093\/eurjpc\/zwac176","article-title":"Including measures of chronic kidney disease to improve cardiovascular risk prediction by SCORE2 and SCORE2-OP","volume":"30","author":"Matsushita","year":"2023","journal-title":"Eur J Prev Cardiol"},{"key":"2026101002222617200_aajag105-B11","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1161\/CIRCULATIONAHA.123.067626","article-title":"Development and validation of the American Heart Association's PREVENT equations [published correction appears in circulation. 2024 mar 12;149(11):e956. Doi: 10.1161\/CIR.0000000000001230.]","volume":"149","author":"Khan","year":"2024","journal-title":"Circulation"},{"key":"2026101002222617200_aajag105-B12","doi-asserted-by":"publisher","first-page":"2054358120922627","DOI":"10.1177\/2054358120922627","article-title":"Validation of the kidney failure risk equation in kidney transplant recipients","volume":"7","author":"Tangri","year":"2020","journal-title":"Can J Kidney Health Dis"},{"key":"2026101002222617200_aajag105-B13","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","journal-title":"Kidney Int"},{"key":"2026101002222617200_aajag105-B14","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC guidelines on cardiovascular disease prevention in clinical practice [published correction appears in eur heart J. 2022 nov 7;43(42):4468. Doi: 10.1093\/eurheartj\/ehac458.]","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"2026101002222617200_aajag105-B15","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","article-title":"2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes [published correction appears in Eur Heart J. 2023 Dec 21;44(48):5060. Doi: 10.1093\/eurheartj\/ehad774.] [published correction appears in Eur Heart J. 2024 Feb 16;45(7):518. Doi: 10.1093\/eurheartj\/ehad857.]","volume":"44","author":"Marx","year":"2023","journal-title":"Eur Heart J"},{"key":"2026101002222617200_aajag105-B16","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/S0140\u20136736(22)02074\u20138","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","author":"Nuffield Department of Population Health Renal Studies Group; SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium","year":"2022","journal-title":"Lancet"},{"key":"2026101002222617200_aajag105-B17","doi-asserted-by":"publisher","first-page":"15922","DOI":"10.1038\/s41598\u2013023\u201342989-z","article-title":"SGLT-2 inhibitors improve cardiovascular and renal outcomes in patients with CKD: a systematic review and meta-analysis","volume":"13","author":"Mavrakanas","year":"2023","journal-title":"Sci Rep"},{"key":"2026101002222617200_aajag105-B18","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/dom.14601","article-title":"Improving the residual risk of renal and cardiovascular outcomes in diabetic kidney disease: a review of pathophysiology, mechanisms, and evidence from recent trials","volume":"24","author":"Chaudhuri","year":"2022","journal-title":"Diabetes Obes Metab."},{"key":"2026101002222617200_aajag105-B19","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.3390\/life13041061","article-title":"Impact of baseline clinical variables on SGLT2i's antiproteinuric effect in diabetic kidney disease","volume":"13","author":"Capelli","year":"2023","journal-title":"Life (Basel, Switzerland)"},{"key":"2026101002222617200_aajag105-B20","volume-title":"uidelines and Statements\u2014Professional AHA","author":"American Heart Association"},{"key":"2026101002222617200_aajag105-B21","author":"Chronic Kidney Disease Prognosis Consortium"},{"key":"2026101002222617200_aajag105-B22","author":"Kidney Failure Risk Project"},{"key":"2026101002222617200_aajag105-B23","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/S2213\u20138587(21)00243\u20136","article-title":"Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial","volume":"9","author":"Jongs","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026101002222617200_aajag105-B24","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.2215\/CJN.0000000000000550","article-title":"Baseline, early changes, and residual albuminuria: post hoc analysis of a randomized clinical trial of dapagliflozin in chronic kidney disease","volume":"19","author":"van Mil","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026101002222617200_aajag105-B25","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.2215\/CJN.02480221","article-title":"Clinical implications of an acute dip in eGFR after SGLT2 inhibitor initiation","volume":"16","author":"Heerspink","year":"2021","journal-title":"Clin J Am Soc Nephrol."},{"key":"2026101002222617200_aajag105-B26","doi-asserted-by":"publisher","first-page":"S165","DOI":"10.2337\/dcS15\u20133006","article-title":"SGLT2 inhibitors and the diabetic kidney","volume":"39","author":"Fioretto","year":"2016","journal-title":"Diabetes Care"},{"key":"2026101002222617200_aajag105-B27","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"2026101002222617200_aajag105-B28","doi-asserted-by":"publisher","first-page":"2636586","DOI":"10.1080\/02813432.2026.2636586","article-title":"Association between statin therapy as primary prevention and mortality in adults 50 years and older with chronic kidney disease without other indications","volume":"44","author":"Malmquist","year":"2026","journal-title":"Scand J Prim Health Care"},{"key":"2026101002222617200_aajag105-B29","doi-asserted-by":"publisher","first-page":"4359","DOI":"10.1093\/eurheartj\/ehaf190","article-title":"2025 focused update of the 2019 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"46","author":"Mach","year":"2025","journal-title":"Eur Heart J"},{"issue":"19","key":"2026101002222617200_aajag105-B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2025.11.016","article-title":"2026 ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of dyslipidemia: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"87","author":"Blumenthal","year":"2026","journal-title":"J Am Coll Cardiol"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/joneph\/article-pdf\/39\/6\/1246\/70632178\/aajag105.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/joneph\/article-pdf\/39\/6\/1246\/70632178\/aajag105.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:22:33Z","timestamp":1791613353000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/39\/6\/1246\/8760812"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":30,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,8,12]]},"published-print":{"date-parts":[[2026,10,10]]}},"URL":"https:\/\/doi.org\/10.1093\/joneph\/aajag105","relation":{},"ISSN":["1121-8428","1724-6059"],"issn-type":[{"value":"1121-8428","type":"print"},{"value":"1724-6059","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,7]]}}}